Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2026-02-01 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - SNT 6 pages 18.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the issuance and quotation of securities resulting from options exercised or convertible securities converted, including specifics about the number of securities, issue dates, and whether they are part of an employee incentive scheme. This type of document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the announcement itself, not just a brief notice or a report publication announcement.
2026-02-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 500.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Report | December 2025' and provides a detailed summary of the company's activities and financial performance for the quarter ended 31 December 2025. It includes clinical pipeline updates, trial progress, regulatory milestones, and a financial section with cash balances and operating cash flows. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is merely an announcement or a presentation, but rather a substantive report with financial and operational data. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2025
2026-01-28 English
2026 Outlook Webinar and Q&A 2 pages 199.8KB
Investor Presentation Classification · 90% confidence The document is a media release announcing an upcoming investor webinar focused on the company's 2026 outlook and clinical pipeline. It includes details about the webinar date, registration, and a company overview. There are no financial statements, detailed financial analysis, or regulatory filings presented. The document is essentially an investor presentation announcement rather than the presentation itself. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Call Transcript. Given the nature of the content as an announcement of an investor event with Q&A, the most appropriate classification is Investor Presentation (IP). The document length is just under 5,000 characters, and it provides substantive information about the event and company strategy, consistent with an investor presentation announcement.
2026-01-28 English
Amsulostat and Garvan in MRFF funded pancreatic trial 3 pages 156.9KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 21 January 2026 from Syntara Limited announcing a $3 million grant from the Medical Research Future Fund (MRFF) to support clinical trials involving their drug candidate amsulostat. The content focuses on the collaboration with the Garvan Institute, details of the clinical trial plans, and background on the drug and company. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a funding grant and clinical trial collaboration, not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement about financing support and clinical development progress, which aligns best with Capital/Financing Update (CAP) as it relates to funding and capital support for clinical trials. The document length is 9067 characters, which is substantial and contains detailed information about the funding and collaboration, not just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2026-01-20 English
SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited 3 pages 164.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 8 January 2026 from Syntara Limited announcing the completion of patient recruitment in a Phase 2 clinical trial for their drug candidate SNT-4728. It provides details about the study design, disease background, and expected top-line results in Q2 CY26. The document is a public announcement of a clinical trial milestone and future data expectations, not a financial report, regulatory filing, or management discussion. It does not contain financial statements, voting results, or governance information. It is not a report publication announcement since it does not mention the release of a report but rather a clinical trial update. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-01-07 English
Company Secretary Appointment/Resignation 2 pages 119.4KB
Board/Management Information Classification · 95% confidence The document is a media release announcing a change in the Company Secretary of Syntara Limited, referencing compliance with ASX Listing Rules 3.16.1 and 12.6. It does not contain financial statements, detailed financial data, or management discussion of financial results. The document is relatively short (4465 characters) and serves as an announcement of a management change rather than a full report or detailed filing. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2026-01-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.